Monitoring Agency Report for the Quarter ended on 30 June 2026

07 August 2026 To To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Dalal Street Complex, Bandra (E), Mumbai – 400 051 Mumbai – 400001 NSE Scrip Symbol: SaiLife BSE Scrip Code: 544306 Sub: Monitoring Agency Report for the quarter ended on 30 June 2026 in relation to the Initial Public Offer (IPO) of the Company. Dear Sir/ Madam, Pursuant to Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 please see attached Monitoring Agency Report for the quarter ended on 30 June 2026 issued by CRISIL Ratings Limited, Monitoring Agency, appointed to monitor the utilisation of proceeds of the IPO of the Company. We request you to take note of the same and oblige. Thank you. For Sai Life Sciences Limited Runa Karan Company Secretary & Compliance Officer Membership No.: A13721 Encl: As above Sai Life Sciences Limited (CIN: L24110TG1999PLC030970) Corporate office Registered office Contact us T: +91 40 6815 6000, # L4-01 & 02, SLN Terminus, Survey Plot No. DS-7, IKP Knowledge Park, Turkapally F: +91 40 6815 6199 #133, Gachibowli Miyapur Road, (V), Shameerpet Mandal, Medchal-Malkajgiri E: info@sailife.com Gachibowli, Hyderabad – 500032, (Dist), Hyderabad -500078, Telangana, India. W: www.sailife.com Telangana, India. Monitoring Agency Report Sai Life Sciences Limited for the quarter ended June 30, 2026 CRL/MAR/SALSCL/2026-27/1951 August 07, 2026 Sai Life Sciences Limited Plot No. DS- 7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal – Malkajgiri District, Hyderabad 500 078, Telangana, India Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Initial Public Offer (“IPO”) of Sai Life Sciences Limited (“the Company”) Pursuant to Regulation 41(2) of SEBI (lssue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated December 05, 2024, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Sai Life Sciences Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: Not applicable (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Sai Life Sciences Limited Names of the promoter: Mr. Ranga Raju Kanumuri Mr. Mytreyi Kanumuri Sai Quest Syn Private Limited Mr. Krishnam Raju Kanumuri Ms. Mytreyi Kanumuri (Partner of Marigold Partners) Ms. Mytreyi Kanumuri (Partner of Tulip Partners) Mr. Ranga Raju Kanumuri (Partner of Sunflower Partners) Mr. Ranga Raju Kanumuri (Partner of Lily Partners) Industry/sector to which it belongs: Healthcare Research, Analytics & Technology 2) Issue Details Issue Period: December 11, 2024, to December 13, 2024 Type of issue (public/rights): Initial Public Offer (IPO) Type of specified securities: Equity Shares IPO Grading, if any: NA Issue size: Rs 30,426.20 million (Fresh issue of Rs 9,500.00 million and OFS of Rs 20,926.20 million) *Note: Particulars Amount (Rs. In million) Gross proceeds of the Fresh Issue 9,500.00# Less: Issue Expenses 401.16$ Net Proceeds 9,098.84 #Crisil Ratings shall be monitoring the gross proceeds. $Out of the issue expenses of Rs 401.16 million, the Company has spent Rs 371.11 million towards the issue expenses as at the quarter ended June 30, 2026, and the remaining Rs 30.05 million are parked in fixed deposits and public offer account of the Company. The above disclosure is based on management undertaking and Certificate dated July 27, 2026, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent Chartered Accountant. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ Comments Comments certifications considered of the of the Particulars Reply by Monitoring Agency Monitoring Board of for preparation of report Agency Directors Proceeds Management are utilised undertaking, Peer- towards Whether all utilization is as per the disclosures reviewed Independent No Yes objects in the Offer Document? Chartered Accountant Comments disclosed in certificate^, Prospectus, Bank Statements prospectus Whether shareholder approval has been obtained in case of material deviations from No No expenditures disclosed in the Offer Comments Comments Document? Whether the means of finance for the disclosed No No objects of the issue has changed? Comments Comments Is there any major deviation observed over the No No earlier monitoring agency reports? Comments Comments Management Whether all Government/statutory approvals No No NA undertaking, Peer- related to the object(s) have been obtained? Comments Comments reviewed Independent Chartered Accountant Whether all arrangements pertaining to certificate^ No No technical assistance/collaboration are in NA Comments Comments operation? Are there any favorable events improving the No No viability of these object(s)? Comments Comments Are there any unfavorable events affecting the No No viability of the object(s)? Comments Comments Is there any other relevant information that No No may materially affect the decision making of NA Comments Comments the investors? NA represents Not Applicable ^Certificate dated July 27, 2026, issued by M/s Bashetty & Joshi, Chartered Accountants (Firm Registration Number: 013299S), Peer-reviewed Independent [Showing first 8,000 characters — download PDF for full document]